8-KEarnings & ResultsExhibits & Filings

AbbVie Inc. 8-K Report, Financial Results (Jan 25, 2019)

Filed January 25, 2019For Securities:ABBV

Summary

AbbVie Inc. (ABBV) filed an 8-K on January 25, 2019, to report its financial results for the fourth quarter and full year ended December 31, 2018. The core of this filing is the press release announcing these results, which provides investors with key performance metrics and financial condition updates. Investors should review this press release for details on revenue, earnings per share, and any forward-looking guidance provided by the company. While the 8-K itself is a notification of the earnings release, the furnished press release (Exhibit 99.1) is the critical document for understanding AbbVie's operational and financial performance during the reported period. This filing serves as the official channel for disseminating this vital information to the market, allowing investors to make informed decisions based on the company's latest financial standing and outlook.

Key Highlights

  • 1AbbVie Inc. filed an 8-K on January 25, 2019, to announce its Q4 and full-year 2018 financial results.
  • 2The press release detailing the financial results is furnished as Exhibit 99.1.
  • 3This filing is primarily a notification to investors about the release of Q4 and FY 2018 financial performance.
  • 4Investors should refer to the furnished press release for specific financial data and performance commentary.
  • 5The event date for the financial results announcement was January 24, 2019.

Frequently Asked Questions

The main purpose of this 8-K filing by AbbVie Inc. on January 25, 2019, is to officially announce and provide access to their financial results for the fourth quarter and the full year ended December 31, 2018, through a furnished press release.

The actual financial results are contained within the press release dated January 25, 2019, which is furnished as Exhibit 99.1 to this 8-K filing and incorporated by reference.

Investors should look for key financial metrics such as revenue for the quarter and full year, earnings per share (EPS), net income, operating income, and any commentary on the performance of key products or therapeutic areas. It is also important to check for any forward-looking guidance provided by the company for upcoming periods.